Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 1/20 | 0.47 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | PLK1 | P53350 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829804 | 0.79 | CYP11B1 (0.55) | PIP4K2APIP4K2BJAK2ABL1CYP11B1 | |
| SCHEMBL3927660 | 0.76 | L3MBTL1 (0.39) | CYP11B1CYP11B2CYP19A1KDM4ENPC1 | |
| SCHEMBL3937644 | 0.73 | NPC1 (0.49) | CYP11B2KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL3938396 | 0.72 | L3MBTL1 (0.60) | KDM4ENPC1RAB9AL3MBTL1MAPT | |
| SCHEMBL3928443 | 0.72 | L3MBTL1 (0.44) | CREBBPKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL3929221 | 0.72 | HPGDS (0.52) | PIP4K2APIP4K2BGSK3BKDM4ENPC1 | |
| SCHEMBL3928842 | 0.72 | METAP2 (0.46) | KDRABL1BRD4KDM4ENPC1 | |
| SCHEMBL3925398 | 0.72 | L3MBTL1 (0.44) | KDRBRD4KDM4ENPC1RAB9A | |
| SCHEMBL3933856 | 0.71 | NPC1 (0.41) | CYP1A2KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL3926887 | 0.70 | NPC1 (0.49) | JAK2KDRABL1CYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | claimed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | claimed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | claimed |
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | PIP4K2A 4139/4885PIP4K2B 4263/4885JAK2 534/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | PIP4K2A 4090/4885PIP4K2B 4221/4885JAK2 511/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | PIP4K2A 4321/4885PIP4K2B 4353/4885JAK2 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.